An anti-Covid nasal spray is coming to Thailand outlets. The spray has been developed in Thailand by the Chulalongkorn University medical faculty in collaboration with Silpakorn University Health Systems Research Institute (HSRI), Government Pharmaceutical Organization, and Hibios Co., Ltd. The spray is designed to block Covid from entering the body through the nose.
The company producing the spray is a subsidiary of Rojukiss International, with the CEO announcing that the nasal spray will be commercially available from Saturday October 1st. The spray will be sold under the brand name ‘VAILL COVITRAP Anti-Cov Nasal Spray’.
A team of doctors and researchers at the prestigious university developed the nasal spray for domestic use. Hopefully, the spray can be a pre-emptive safety measure against coronavirus infections using antibody technology specific to COVID-19.
The nasal spray works by coating the inside of your nose with hydroxypropyl methylcellulose. That creates a barrier in the pores, blocking the Covid virus from being absorbed into the body through the nasal cavity. Ingesting the spray in doses every six hours or three times per day is said to protect users from the virus.
The director of the Health System Research Institute hailed the Thai creation as innovative. Hibios has now registered patent rights for the nasal spray which is now ready for commercial distribution and sales.
Information about the new Thai nasal spray is available through Facebook at https://www.facebook.com/covitrap and using the @Covitrap account on the LINE app. The Government Pharmaceutical Organisation also now informed pharmacists, medical clinics and drug stores.
